Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Danish Dairy Research Foundation, Denmark | OTHER |
| Dairy Research Institute | OTHER |
| Dairy Farmers of Canada | OTHER |
| Centre National Interprofessionel de l'Economie Laitière |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall aim of the present research project is to examine whether consumption of high daily amounts of cheese, both high-fat and low-fat, affects risk markers of disease in a study population of men and women with metabolic syndrome risk factors.
It will be explored whether high-fat and/or low-fat cheese consumption can be regarded healthy to consume for at-risk populations (assessed by within-group comparisons from baseline values) and if low-fat or non-fat alternatives to high-fat cheese should continue to be recommended (assessed by between-group comparisons).
In addition, it will be assessed if cheese consumption affects women and men differently as suggested by observational data. The present research project will examine the health effects of cheese as a food product per se and not as a sum of single nutrients, knowing that the single components of cheese cannot be adequately placebo-matched. A relatively high daily intake of high-fat cheese will be compared to a similar intake of low-fat cheese and with a carbohydrate control.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High-fat cheese (HFC) group | Experimental | The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US). No further dairy and cheese consumption is allowed |
|
| Low-fat cheese (LFC) group | Experimental | The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed. |
|
| No-cheese/carbohydrate group (CTR) | Active Comparator | For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High-fat cheese | Dietary Supplement |
| ||
| Low-fat cheese |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in LDL cholesterol from baseline to post-intervention | fasting, mmol/l | week 1 and week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Blood lipid concentrations | Total and HDL cholesterol - fasting (mmol/l) Triglycerides - fasting (mmol/l) | week 1 and week 12 |
| Particle size | HDL, VLDL and LDL particle size (by NMR) |
Not provided
Inclusion Criteria:
Men or women
Age 18-70
Waist circumference > 80 cm for women / > 94 cm for men
Plus at least one additional established risk factor for the metabolic syndrome using the following criteria:
Exclusion Criteria:
Chronic diseases (known diabetes; cardiovascular disease; other chronic diseases which could affect the results of the present study)
Milk allergy
Use of dietary supplements incl. multivitamins (2 months before and during the entire study period)
>10 hours of strenuous physical activity per week
Use of prescription medicine which could affect the results of the present study including systemic glucocorticoids or medicine which have interactions with the intervention products (safety)
Drug or alcohol abuse
Blood donation <1 month before study commencement and during study period
Simultaneous participation in other clinical studies
Pregnant or lactating women, or women who are planning to become pregnant within the next 6 months.
Inability to comply with the procedures required by the protocol
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arne Astrup, Prof, MD | Head of Department of Nutrition, Exercise and Sports | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Nutrition, Exercise and Sport | Copenhagen | Frederiksberg | 1958 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27557654 | Derived | Raziani F, Tholstrup T, Kristensen MD, Svanegaard ML, Ritz C, Astrup A, Raben A. High intake of regular-fat cheese compared with reduced-fat cheese does not affect LDL cholesterol or risk markers of the metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2016 Oct;104(4):973-981. doi: 10.3945/ajcn.116.134932. Epub 2016 Aug 24. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
| OTHER |
| Dairy Australia | INDUSTRY |
| Nederlandse Zuivel Organisatie | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| Dietary Supplement |
|
| No-cheese/carbohydrate | Dietary Supplement |
|
| week 1 and week 12 |
| Anthropometry | Hip circumference (cm) Waist circumference (cm) Weight (kg) | 5 times during the 12-week intervention |
| Blood pressure (BP) | Systolic BP (mmHG) Diastolic BP (mmHG) | 3 time during the 12-week intervention |
| Insulin sensitivity | Plasma glucose - fasting (mmol/l) Plasma insulin - fasting (mmol/l) | week 1 and week 12 |
| Inflammation | Serum C-reactive protein - fasting (mmol/l) | week 1 and week 12 |
| Postprandial markers of lipid metabolism | Measurements in a sub-group | week 12 |
| Postprandial markers of glucose metabolism | Measurements in a sub-group | week 12 |
| Postprandial appetite sensation (by VAS) | Measurements in a sub-group | week 12 |